Neurocrine Biosciences (NASDAQ:NBIX) Sets New 52-Week High – Time to Buy?

Posted by Stanley Muller on Jun 29th, 2026

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $170.97 and last traded at $170.6810, with a volume of 77203 shares traded. The stock had previously closed at $168.52.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NBIX. HC Wainwright boosted their price objective on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Piper Sandler increased their target price on Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Citigroup lifted their price target on Neurocrine Biosciences from $242.00 to $246.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Needham & Company LLC restated a “buy” rating and issued a $185.00 price target on shares of Neurocrine Biosciences in a report on Monday, April 6th. Finally, Leerink Partners upped their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $187.52.

Read Our Latest Stock Report on NBIX

Neurocrine Biosciences Price Performance

The stock’s 50-day moving average price is $151.99 and its 200 day moving average price is $141.15. The firm has a market cap of $17.13 billion, a P/E ratio of 26.25, a price-to-earnings-growth ratio of 0.67 and a beta of 0.39.

Insider Transactions at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 2,261 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $156.71, for a total transaction of $354,321.31. Following the completion of the transaction, the insider directly owned 16,225 shares in the company, valued at $2,542,619.75. This represents a 12.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $160.25, for a total value of $1,762,750.00. Following the completion of the transaction, the insider owned 25,846 shares of the company’s stock, valued at $4,141,821.50. The trade was a 29.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 355,234 shares of company stock worth $55,330,060. 4.60% of the stock is owned by insiders.

Institutional Trading of Neurocrine Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of NBIX. USA Financial Formulas acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth approximately $25,000. DJE Kapital AG acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $28,000. Geneos Wealth Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 651.6% in the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after buying an additional 202 shares during the last quarter. Finally, Basecamp Wealth Advisors LLC grew its stake in shares of Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after buying an additional 204 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.